Altimmune (NasdaqGM:ALT) - Share price, News & Analysis

ALT fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

ALT Stock Overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

Rewards

Revenue is forecast to grow 92.69% per year

Risk Analysis

Earnings are forecast to decline by an average of 13.8% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have meaningful revenue ($4M)

Altimmune Competitors

Emergent BioSolutions

NYSE:EBS

US$1.4b

Price History & Performance

Summary of all time highs, changes and price drops for Altimmune
Historical stock prices
Current Share Price	US$5.16
52 Week High	US$19.46
52 Week Low	US$3.83
Beta	1.44
1 Month Change	-1.34%
3 Month Change	-31.11%
1 Year Change	-61.43%
3 Year Change	110.61%
5 Year Change	-96.12%
Change since IPO	-97.83%

Recent News & Updates

Apr 07

Altimmune's New Avatar As A Liver Disease Player

Altimmune used to be an infectious disease player. After a lot of upheavals last year, it has now moved on to obesity, NASH and NAFLD. I am curious to see how this evolves.

Shareholder Returns

	ALT	US Biotechs	US Market
7D	19.2%	0.1%	-2.5%
1Y	-61.4%	-21.7%	-10.4%

Return vs Industry: ALT underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: ALT underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is ALT's price volatile compared to industry and market?
ALT volatility
ALT Average Weekly Movement	11.5%
Biotechs Industry Average Movement	12.3%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	2.8%

Stable Share Price: ALT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ALT's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1997	47	Vipin Garg	https://altimmune.com

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

Altimmune Fundamentals Summary

How do Altimmune's earnings and revenue compare to its market cap?
ALT fundamental statistics
Market Cap	US$221.43m
Earnings (TTM)	-US$101.66m
Revenue (TTM)	US$3.60m

61.4x

P/S Ratio

-2.2x

P/E Ratio

Is ALT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALT income statement (TTM)
Revenue	US$3.60m
Cost of Revenue	US$79.73m
Gross Profit	-US$76.12m
Other Expenses	US$25.53m
Earnings	-US$101.66m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.37
Gross Margin	-2,111.97%
Net Profit Margin	-2,820.39%
Debt/Equity Ratio	0%

How did ALT perform over the long term?

See historical performance and comparison

Valuation

Is Altimmune undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

1.2x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: ALT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALT is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALT's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ALT is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (1.4x).

Future Growth

How is Altimmune forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-13.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALT's revenue (92.7% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: ALT's revenue (92.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALT's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Altimmune performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-22.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALT is currently unprofitable.

Growing Profit Margin: ALT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ALT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.

Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: ALT has a negative Return on Equity (-54.99%), as it is currently unprofitable.

Financial Health

How is Altimmune's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALT's short term assets ($191.1M) exceed its short term liabilities ($19.1M).

Long Term Liabilities: ALT's short term assets ($191.1M) exceed its long term liabilities ($1.7M).

Debt to Equity History and Analysis

Debt Level: ALT is debt free.

Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 14.5%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALT has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 45% each year.

Dividend

What is Altimmune current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALT has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure

CEO

Vipin Garg (63 yo)

3.5yrs

Tenure

US$2,631,639

Compensation

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

CEO Compensation Analysis

Compensation vs Market: Vipin's total compensation ($USD2.63M) is above average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: ALT's management team is considered experienced (3.7 years average tenure).

Board Members

Experienced Board: ALT's board of directors are considered experienced (5 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/15 00:00
End of Day Share Price	2022/05/13 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31